2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction

BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV, GSK), indicated for the prevention of herpes zoster (HZ) in adults ≥ 50 years of age, received its first marketing authorization in October 2017. We reviewed the post-marketing spontaneous adverse event (AE) reports submitted to GSK’s world...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares-Da-Silva, Fernanda, Miranda Co, Maribel, Dessart, Cristophe, Hervé, Caroline, López-Fauqued, Marta, Mahaux, Olivia, Van Holle, Lionel, Stegmann, Jens-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810355/
http://dx.doi.org/10.1093/ofid/ofz360.2453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810355/
http://dx.doi.org/10.1093/ofid/ofz360.2453

Ejemplares similares